Poly-MVA® and prostate health: Shari Lieberman PhD, CNS, FACN discusses cancer case studies with the Foundation for Advancement in Cancer Research

Townsend Letter for Doctors and Patients, August-Sept, 2006

Immediately after taking the Poly-MVA, his PSA temporarily rose to 5.6 in November 2004. It is unknown whether this elevation was the result of the biopsy he had or the possible tumor-killing effect of the product. By December 2004, his PSA level decreased to 4.01. His last PSA in March 2005 was 2.8, and his prostate nodules were no longer palpable. His dysuria and hematuria completely resolved, and he scored 100% on a performance scale. In addition, his lymphocytes rose to 19.3 in January 2005. He remains mentally, physically, and sexually active.

FACR: It sounds as if Poly-MVA may have the ability to influence markers of prostate health.

Dr. Lieberman: Exactly. And the same results were achieved in another case report. When 77-year-old M.O. was diagnosed with stage 4 adenocarcinoma of the prostate in October 1996, his PSA was 69.2. He refused chemotherapy, radiation, or surgery but agreed to hormonal blockade treatment. After this treatment, his PSA declined to 15.3 by November 2001 and then went up to 27.9 by December 2003. He stopped part of the hormonal blockade treatment when he developed gynecomastia (enlargement of breast tissue in the male) and continued to have back pain. By January 2002, his PSA was 32, and he stopped all hormonal treatment. He began taking two teaspoons q.i.d. of Poly-MVA in February 2004 for six months. Thereafter, he consumed two teaspoons b.i.d. His PSA level decreased to 0.4 in July 2004 and rose slightly to 0.5 in September 2004. M.O. was last seen in February 2005 when his PSA rose to 9. During this last visit, despite the rise in PSA, his back pain had resolved, and his performance scale was 100%. His comprehensive metabolic panel showed normal results. However, his gynecomastia did not resolve. He has been instructed to reinstate his oral dose of Poly-MVA at two teaspoons q.i.d.

FACR: We are interested in other types of cancer, how does POLY-MVA affect lung cancer?

Dr. Lieberman: Lung cancer is the leading cause of cancer death worldwide. In the US alone, there are more than 170,000 new cases diagnosed each year, with an annual death rate of approximately 160,000. It remains the leading cause of cancer-related mortality in both sexes, accounting for 32% of cancer deaths in men and 24% of cancer deaths in women. The five-year survival statistics for patients with lung cancer remain bleak--almost all of these patients eventually die of their disease, and the overall five-year survival rate remains at five to seven percent. Non-small-cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases.

FACR: Are there any case studies on lung cancer and Poly-MVA?

Dr. Lieberman: Yes, the case study of a 65-year-old female who was diagnosed with stage 4 non-small cell lung cancer (NSCLC). The patient remained well and had a good quality of life despite failing chemotherapy, Iressa, and Tarceva therapy while taking Poly-MVA. However, she had acquired multi-drug resistance, and her tumor markers continued to rise. As a last resort, her oncologist used a very old chemotherapeutic regimen (which is generally not used anymore), plus the Poly-MVA, which caused her tumor markers to drop dramatically. For the first time, she experienced significant clearing of metastasis on her CT scan.